Abstract library

2316 results for "nonfunctioning neuroendocrine tumor".
#991 Primary Neuroendocrine Tumor of Extrahepatic Bile Duct
Introduction: Biliary tract primary malignant tumors are rare neoplasms. Eighty-five per cent are cholangiocarcinomas, being in exceptional cases a neuroendocrine tumor. The absence of clinical suspiction involves a difficult preoperative diagnosis.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Jose Angel Flores Garcia
#724 Contrast-Enhanced Ultrasonography (CEUS) Reliably Predicts Tumor Progression in Pancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) exhibit a typical vascular pattern in the arterial phase on CEUS. The role of CEUS in the prognostic evaluation of pancreatic NET (pNET) has been poorly investigated.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Michela Del Prete
#37 Gastric GIST with synchronous neuroendocrine tumor of the pancreas, Case Report and Literature Review
Introduction: The Gastrointestinal Stromal Tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. These are rare tumors with an incidence of 15 new cases per million per year. They often occur in individuals over the age of 40 years, without gender predominance. The clinical behavior is variable and benign tumors are the most common. They can develop anywhere in the GI tract, but are more frequent in the stomach and small intestine. The primary treatment, when located, is the surgical resection, which can be complemented with the use of imatinib.
The occurrence of neuroendocrine tumors of the pancreas is rare, representing 1-5% of pancreatic cancers, and it is estimated that its incidence does not exceed 5 to one million. The tumors considered nonfunctioning (15-32% of pancreatic neuroendocrine tumors) are not associated with any syndrome, and are usually incidental. They have a slight predominance in males, and are more frequent in the 6th decade of life. Nonfunctioning tumors of islet cells are virtually all malignant tumors, and the treatment consists of surgical resection.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dra Amelia B Tavares
#630 Pancreatic Polypeptide Cell Hyperplasia Associated with Nonfunctioning Pancreatic Neuroendocrine Tumor: A Case Report
Introduction: A case report of pancreatic polypeptide (PP) cell hyperplasia in association with nonfunctioning pancreatic neuroendocrine tumor (NET).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Aleksandar Prazic
#2200 Tumor Size Correlates with Grading in Nonfunctioning Pancreatic Neuroendocrine Tumors and Is Not Age-Dependent
Introduction: Tumor growth and Ki67 value increase are associated with aggressiveness in nonfunctioning pancreatic neuroendocrine tumours (NF-PanNET), but their natural history is largely unknown. It is unknown if the evolution of NF-PanNET is time-dependant.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Francesca Muffatti
#2961 Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: For patients with nonfunctioning pNET  ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.
Conference: 17th Annual ENETS Conference (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Laura Mastrangelo
#544 Second Primary Tumor in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): Data From a Retrospective Observational Unicentric Study
Introduction: It is known that GEPNETs are associated with a high incidence of second primary tumors, especially in the context of inherited syndromes and synchronous injuries to the intestine.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Paula J Fonseca
#2856 Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.
Conference: 17th Annual ENETS Conference (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Valentina Andreasi
#1265 Prognostic Factors for Recurrence of Sporadic Pancreatic Neuroendocrine Tumors After Surgical Resection
Introduction: Pancreatic neuroendocrine tumors (PNET) are rare neoplasms with heterogeneous presentation. The diagnosis of malignancy is often difficult, and then further studies may contribute to improve prognosis criteria.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: PhD Estela Regina Ramos Figueira
#1851 Ecological Study to Assess the Management of Gastroenteropancreatic Neuroendocrine Tumors in Spain
Introduction: Neuroendocrine tumors (NET) have widely varying characteristics, localizations, and treatments. Consequently, a multidisciplinary approach to diagnosis and treatment is necessary. Given the heterogeneous management of this disease, we conducted an ecological survey to assess usual clinical practice in Spain.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Raquel Guardeño
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team